Professor (University of Michigan); Section Chief, Cardiology (VA Ann Arbor)
University of Michigan

Printed as of 12/4/2025

Disclosures

Personal Commercial (5)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
Alleviant Medical	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Axon Therapeutics	Research/Research Grants ‡ REBALANCE-HF (site PI)	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Corvia	Research/Research Grants ‡ REDUCE LAP-HF (site PI), REDUCE LAP-HF 2 (site PI), RESPONDER-HF (site PI)	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Intellia Therapeutics	Research/Research Grants	Significant (>= \$5,000)	Other
Novartis	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (7)

Non-Commercial Enity Name	Relationship Category	Compensation Level	Topic Area(s)
Self			
AHRQ	Research/Research Grants	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
American Heart Association	Research/Research Grants	Significant (>= \$5,000)	Other
NIH/NHLBI	Research/Research Grants ‡ SPIRRIT-HFpEF (site PI)	Modest (< \$5,000)	Heart Failure and Cardiomyopathies
NIH/NHLBI	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
NIH/NIA	Research/Research Grants	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Veterans Health Administration	Research/Research Grants ‡ Cooperative Study #2025 (Study Chair)	Significant (>= \$5,000)	Heart Failure and Cardiomyopathies
Veterans Health Administration	Research/Research Grants	Significant (>= \$5,000)	Prevention

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

No disclosures on record

Expert Witness Testimony (0)

No disclosures on record

† Commercial Funding Source | ‡ Trial Name

Agreement

Certified Education Attestation | Signed on 10/15/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement in the property of the prope

Confidentiality, Disclosure and Assignment Agreement | Signed on 10/15/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement

Embargo | Signed on 10/15/2025

URL for full agreement: http://disclosures.acc.org/Public/Definition/EmbargoAgreement

On-Going Obligation Agreement | Signed on 10/15/2025

ACC and **Disclosures**

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.